Efinopegdutide Cost Breakdown: Brand, Compounded, Insurance & Savings Options

Introduction

Efinopegdutide isn’t FDA-approved yet, so no commercial pricing exists in 2026. Merck is developing the drug primarily for MASH, which affects the likely pricing strategy and insurance coverage outlook. Reasonable forecasts put efinopegdutide’s launch price in the $1,000 to $1,500/month range, similar to brand GLP-1 drugs.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Will Efinopegdutide Cost When Approved?

Forecasting depends partly on which indication Merck pursues first. If the lead approval is MASH, pricing may compare to Rezdiffra® ($47,400/year, or about $3,950/month). If the lead is obesity, pricing may compare to Wegovy® and Zepbound® ($1,000 to $1,500/month).

Quick Answer: Efinopegdutide is not FDA-approved and not available outside clinical trials

Merck has the corporate scale to price aggressively or competitively. Most likely outcome is something in the $1,000 to $1,500/month range for obesity and possibly $1,500 to $2,500/month if MASH-specific.

Actual paid prices are typically 30 to 60% below list because of rebates and PBM negotiation. Manufacturer copay assistance can bring out-of-pocket costs to $25/month for eligible insured patients.

Why Isn’t There Compounded Efinopegdutide?

Compounded efinopegdutide isn’t legal because the drug isn’t FDA-approved. Compounding is only permitted for FDA-approved drugs in specific circumstances (shortage status, individual patient need that can’t be met by approved product).

Online vendors selling efinopegdutide as a “research peptide” operate in a gray-to-illegal zone. Quality, purity, and dosing accuracy can’t be verified. Patients should avoid these products.

Once efinopegdutide is FDA-approved, compounding might be possible if shortages occur. Whether that happens depends on Merck’s manufacturing capacity at launch.

How Does Efinopegdutide Pricing Compare to Current GLP-1 Drugs?

Wegovy and Zepbound retail around $1,059 to $1,349/month. With manufacturer savings cards, eligible patients pay $0 to $25 in the first months and similar low amounts with insurance.

Compounded semaglutide and tirzepatide through telehealth platforms typically run $150 to $400/month. TrimRx prices fall in this range. Compounding is currently permitted because of FDA-declared shortages of brand drugs.

Efinopegdutide at launch will likely be in the brand range. Compounded versions probably won’t exist for at least a year or two after approval.

Will Insurance Cover Efinopegdutide?

Coverage depends on indication. If approved for MASH, coverage may be easier because MASH is a recognized chronic disease with multiple FDA-approved therapies (resmetirom in 2024) and existing reimbursement pathways.

If approved for obesity alone, coverage faces the same patchwork that affects Wegovy and Zepbound. Many commercial plans cover obesity drugs with step therapy or BMI requirements. Medicare excludes obesity-only drugs by statute.

The most likely scenario is dual approval (MASH and obesity) or sequential approval (MASH first, obesity second). Coverage will be best for MASH indication.

What About the Manufacturer Savings Card Option?

Merck has experience with copay assistance programs for other drugs (Januvia, Keytruda, etc.). Efinopegdutide will likely have a similar program at launch, capping monthly out-of-pocket at $0 to $25 for commercially insured eligible patients.

Government insurance (Medicare, Medicaid, Tricare) typically can’t stack with manufacturer savings programs. Patients with these plans either pay full price (if uncovered) or copays (if covered) without manufacturer assistance.

What’s the Cash-pay Outlook?

Direct cash-pay channels have emerged for Wegovy and Zepbound. Efinopegdutide will likely have a similar option at launch, especially if Merck wants to compete on access.

Cash prices in the $400 to $700/month range have become standard for direct manufacturer channels. Compounded GLP-1s remain cheaper ($150 to $400/month through TrimRx and similar) while shortage-based compounding remains possible.

How Does the MASH Indication Change the Math?

MASH is a chronic progressive liver disease. Specialty pharmacy and hepatology coverage of MASH drugs is more aggressive than obesity-only coverage. Rezdiffra (resmetirom) achieved broad commercial coverage shortly after FDA approval.

If efinopegdutide gets MASH approval, insurance plans may cover it for MASH patients (with documented disease, often biopsy-proven) even when obesity-only patients face barriers.

Coverage criteria for MASH typically include biopsy or non-invasive testing showing significant fibrosis, prior treatment with diet and exercise, and absence of other liver diseases.

Are There Cheaper Alternatives While Waiting for Efinopegdutide?

Yes. Compounded semaglutide and tirzepatide through telehealth platforms like TrimRx are the most affordable GLP-1 options ($150 to $400/month).

For MASH specifically, lifestyle modification remains first-line. Resmetirom (Rezdiffra) is FDA-approved but expensive. Semaglutide may receive a MASH indication based on phase 3 ESSENCE data (top-line 2024).

For patients prioritizing weight loss, compounded GLP-1s offer the best price-effectiveness ratio while shortages permit compounding.

What Does the TrimRx Free Assessment Quiz Factor In?

The TrimRx quiz currently screens for clinical fit with compounded semaglutide or tirzepatide. It includes liver health history, weight loss goals, medical comorbidities, and other factors relevant to GLP-1 therapy.

When efinopegdutide is approved, TrimRx will evaluate adding it. The personalized treatment plan would match patients with significant MASH to efinopegdutide (if approved for MASH) and patients without significant MASH to semaglutide or tirzepatide.

How Does Pricing Scale with Dose?

Most GLP-1 drugs are priced by pen or dose unit, not by milligram. Efinopegdutide will likely follow the same convention: one weekly injection at a single per-injection price, regardless of dose.

That means dose reductions don’t usually save money unless the patient is able to stop therapy entirely or move to less frequent dosing.

Can Patients Combine Savings Programs and Insurance?

Manufacturer savings cards stack with most commercial insurance. The card covers the patient’s copay portion (up to limits), insurance pays the rest, total monthly cost is often $25 or less.

Government insurance generally cannot stack with manufacturer programs.

Patients should check Merck’s savings card terms once efinopegdutide is approved to confirm eligibility and program structure.

What’s the Realistic Monthly Cost for Most Patients?

Most patients on efinopegdutide will pay:

$0 to $25/month with commercial insurance and manufacturer savings card.

$400 to $700/month through direct cash channels without insurance.

$1,000 to $2,500/month at full retail without coverage or savings (range depends on whether obesity or MASH pricing applies).

Compounded GLP-1 alternatives (semaglutide, tirzepatide) through TrimRx and similar remain in the $150 to $400/month range for patients seeking the most affordable option.

Key Takeaway: Wegovy lists at about $1,349/month, Zepbound at about $1,059/month

How Might Pricing Evolve Over Time?

GLP-1 drug pricing has been remarkably stable since launches of Wegovy (2021) and Zepbound (2023), with list prices increasing modestly each year. Net prices to insurers have fluctuated more, driven by rebate negotiations and PBM dynamics.

For efinopegdutide, expect:

Launch pricing at parity with current brand GLP-1 drugs ($1,000 to $1,500/month) or moderately higher if positioned for MASH ($1,500 to $2,500/month).

Annual list price increases of about 3 to 5%.

Net prices to insurers significantly below list because of competitive pressure from multiple GLP-1 options.

Manufacturer copay programs continuing to make commercial-insured patient out-of-pocket affordable.

What About Patient Assistance Programs?

Merck has well-established Patient Assistance Programs (PAPs) for many of its drugs. Eligibility typically requires being uninsured or having income below specific thresholds (often 400 to 500% of federal poverty level), being a US resident, and having no other access path to the medication.

Patients who qualify can receive the drug at no cost or significantly reduced cost. The application process involves income verification and physician documentation.

These programs typically launch alongside new drug approvals. When efinopegdutide is approved, Merck will likely include a PAP option.

How Does Pemvidutide Compete on Price?

Pemvidutide (Altimmune) and efinopegdutide (Merck) are both in late-stage development with similar positioning. Whichever launches first may set the price benchmark for the dual GLP-1/glucagon class.

Altimmune is smaller than Merck and may need to price aggressively to compete. Merck has larger resources but may prefer parity pricing to avoid commoditizing its product.

Patients should compare specific manufacturer programs and insurance coverage when both drugs are available.

What About International Pricing?

US drug prices are typically 2 to 4x higher than European prices for the same brand drugs. Wegovy in the UK costs about 200 to 250 GBP per month at private pharmacy prices versus $1,349 list in the US.

Efinopegdutide is likely to follow the same pattern. International availability depends on regulatory approvals in each market.

For US patients, importing from international pharmacies isn’t generally legal for prescription drugs, though the FDA has historically taken limited enforcement action against personal-use imports.

What’s the Cost of Clinical Trial Participation?

Trial participation is free. Patients receive the study drug at no cost, study visits and tests are covered by the sponsor, and many trials provide modest compensation for time and travel.

Patients interested in efinopegdutide trials can search clinicaltrials.gov. Enrollment requires meeting study eligibility criteria, which typically includes specific BMI ranges, MASH diagnosis (for MASH trials), and exclusion of major comorbidities.

How Does the TrimRx Assessment Factor Cost Considerations?

The TrimRx free assessment quiz captures insurance status and budget considerations alongside clinical factors. The personalized treatment plan accounts for cost when matching patients to medications.

For most TrimRx patients today, compounded semaglutide or tirzepatide is the most affordable option ($150 to $400/month). Brand drugs are recommended when insurance coverage makes them affordable or when specific clinical needs favor brand formulations.

When efinopegdutide is available, the same cost-benefit analysis will apply.

Will Competition Drive Prices Down?

As more GLP-1 drugs reach market (efinopegdutide, pemvidutide, retatrutide, survodutide, CagriSema), price competition should increase. By 2030, the GLP-1 market may have 6 to 8 approved options, which historically drives both list and net prices down.

Generic semaglutide and tirzepatide could enter as patents expire (semaglutide’s main patent expires in 2031 in most markets). Generic competition would dramatically reduce prices.

What About Hospital and Specialty Pharmacy Distribution?

Specialty pharmacies handle many high-cost biologic drugs including some GLP-1 drugs. If efinopegdutide is positioned for MASH, it may be distributed primarily through specialty pharmacies rather than retail.

Specialty pharmacy distribution typically involves:

Direct shipment to patient or clinic.

Insurance prior authorization handling.

Patient assistance with copay programs.

Clinical support for adherence.

This can be helpful but also adds steps versus retail pharmacy pickup.

How Might Value-based Pricing Apply?

Some payers are exploring value-based pricing arrangements where drug costs depend on outcomes (weight loss achieved, MASH resolution achieved, etc.). These arrangements are uncommon but growing.

Efinopegdutide may be a candidate for value-based deals especially in MASH where outcome milestones (biopsy improvements) are measurable.

What’s the Total Cost of GLP-1 Therapy Over Time?

A patient on efinopegdutide for 5 years at $1,000/month (estimated cash net price after savings card) would pay roughly $60,000 over that period. Insured patients might pay $1,500 over 5 years ($25/month).

The cost calculus changes if the therapy reduces other health care utilization (avoided cardiovascular events, avoided liver disease progression, reduced diabetes complications). Quality-adjusted life year (QALY) analyses for GLP-1 drugs have shown favorable cost-effectiveness in obesity and MASH.

Bottom line: MASH coverage tends to be easier to obtain than obesity-only coverage

FAQ

When Will Efinopegdutide Be Available and How Much?

Earliest realistic launch is 2027 to 2028. Pricing isn’t set; likely $1,000 to $2,500/month depending on indication.

Can I Get Compounded Efinopegdutide Cheaper?

No. Compounding isn’t legal because the drug isn’t FDA-approved.

Will Medicare Cover Efinopegdutide?

For MASH, probably yes once approved (Medicare covers other MASH drugs). For obesity alone, probably not (statutory exclusion).

Do Clinical Trials Offer Free Efinopegdutide?

Yes. Trial participants get the drug at no cost. Enrollment requires meeting eligibility criteria.

How Does Efinopegdutide Cost Compare to Semaglutide?

At launch, retail prices similar. Compounded semaglutide is cheaper now because of shortage-based compounding, an option efinopegdutide won’t have at launch.

Will Insurance Cover Efinopegdutide for MASH but Not Obesity?

Possibly. MASH coverage tends to be easier to obtain than obesity-only coverage.

What’s the Most Affordable GLP-1 Option in 2026?

Compounded semaglutide and tirzepatide through telehealth services like TrimRx ($150 to $400/month) are typically the most affordable.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.